◐ Shell
reader mode source ↗
Skip to main page content
Full text links Cite
Display options

Abstract

Since April 2024, sporadic infections with highly pathogenic avian influenza (HPAI) A(H5) viruses have been detected among dairy farm workers in the United States. To date, infections have mostly been detected through worker monitoring, and have been mild despite the possibility of more severe illness. During June-August 2024, CDC collaborated with the Michigan Department of Health and Human Services and the Colorado Department of Public Health and Environment to implement cross-sectional serologic surveys to ascertain the prevalence of recent infection with HPAI A(H5) virus among dairy workers. In both states, a convenience sample of persons who work in dairies was interviewed, and blood specimens were collected. Among 115 persons, eight (7%; 95% CI = 3.6%-13.1%) had serologic evidence of recent infection with A(H5) virus; all reported milking cows or cleaning the milking parlor. Among persons with serologic evidence of infection, four recalled being ill around the time cows were ill; symptoms began before or within a few days of A(H5) virus detections among cows. This finding supports the need to identify and implement strategies to prevent transmission among dairy cattle to reduce worker exposures and for education and outreach to dairy workers concerning prevention, symptoms, and where to seek medical care if the workers develop symptoms. Timely identification of infected herds can support rapid initiation of monitoring, testing, and treatment for human illness, including mild illness, among exposed dairy workers.

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

References

    1. Levine MZ, Holiday C, Liu F, et al. Cross‐reactive antibody responses to novel H5Nx influenza viruses following homologous and heterologous prime‐boost vaccination with a prepandemic stockpiled A(H5N1) vaccine in humans. J Infect Dis 2017;216(Suppl 4):S555–9. 10.1093/infdis/jix001 - DOI - PMC - PubMed
    1. Levine MZ, Holiday C, Jefferson S, et al. Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost. NPJ Vaccines 2019;4:22. 10.1038/s41541-019-0114-8 - DOI - PMC - PubMed
    1. Toner ES, Adalja AA, Nuzzo JB, Inglesby TV, Henderson DA, Burke DS. Assessment of serosurveys for H5N1. Clin Infect Dis 2013;56:1206–12. 10.1093/cid/cit047 - DOI - PMC - PubMed
    1. Chen X, Wang W, Wang Y, et al. Serological evidence of human infections with highly pathogenic avian influenza A(H5N1) virus: a systematic review and meta-analysis. BMC Med 2020;18:377. 10.1186/s12916-020-01836-y - DOI - PMC - PubMed
    1. Gomaa M, Moatasim Y, El Taweel A, et al. We are underestimating, again, the true burden of H5N1 in humans. BMJ Glob Health 2023;8:e013146. 10.1136/bmjgh-2023-013146 - DOI - PMC - PubMed
Show all 10 references

MeSH terms

Substances